Decreased suppression of interleukin-6 after treatment with medroxyprogesterone acetate and danazol in endometrial stromal cells of women with adenomyosis.
OBJECTIVE
To examine changes in local cytokine production in the eutopic endometrium of adenomyosis after treatment with medroxyprogesterone acetate (MPA) and danazol.


METHODS
Prospective cohort study.


METHODS
Tertiary university hospital.


METHODS
Twenty-four women with adenomyosis (study group) and 22 women without adenomyosis (control group).


METHODS
Eutopic endometrium was separated into single endometrial stromal cells (ESCs), and was cultured in vitro alone, with MPA (10(-7) M), or with danazol (10(-7) M) for 8 days.


METHODS
Messenger RNA expression of interleukin (IL)-6, IL-8, and tumor necrosis factor-alpha in ESCs, and their concentrations in the supernatants of ESCs.


RESULTS
A significant decrease of IL-6 concentration in the supernatant, measured by ELISA, was found with time of ESCs cultured with MPA and danazol in the control group, but not in adenomyosis. The IL-6 mRNA in ESCs determined by real-time quantitative polymerase chain, as well as its concentration in the supernatant, was much higher in adenomyosis than that in the control group after treatment with MPA and danazol for 8 days.


CONCLUSIONS
Medroxyprogesterone acetate and danazol appeared to have a decreased effect on the suppression of IL-6 liberated by ESCs in adenomyosis. This aberrant secretion of IL-6 might play a role in the formation of ectopic endometrial implants in adenomyosis.
Yang
Jehn-Hsiahn
JH
Department of Obstetrics and Gynecology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
Chen
Mei-Jou
MJ
Wu
Ming-Yih
MY
Chen
Yi-Chun
YC
Yang
Yu-Shih
YS
Ho
Hong-Nerng
HN
D002478:Cells, Cultured; D015331:Cohort Studies; D003271:Contraceptive Agents, Female / Q000008:administration & dosage; D003613:Danazol / Q000008:administration & dosage*; D004338:Drug Combinations; D004715:Endometriosis / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D004717:Endometrium / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D004965:Estrogen Antagonists / Q000008:administration & dosage; D005260:Female; D015870:Gene Expression / Q000187:drug effects; D006801:Humans; D015850:Interleukin-6 / Q000378:metabolism*; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage*; D017154:Stromal Cells / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D014591:Uterine Diseases / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology
D003271:Contraceptive Agents, Female; D004338:Drug Combinations; D004965:Estrogen Antagonists; D015850:Interleukin-6; D017258:Medroxyprogesterone Acetate; D003613:Danazol